Phase 2 N=12 Use of Donepezil for Treatment of Cocaine Dependence
Cocaine Abuse and Dependence
Primary: Cocaine Safety in Subjects Receiving Donepezil — 0; 2 Participants with an Adverse Event
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
Breast Cancer
Primary: Confirmed Response Rate (Complete and Partial) — 2 participants
Phase 2 N=64 Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: The Proportion of Patients Alive and Without Progressive Disease (PD) for ≥6 Months — 75 percentage of treated patients
Phase 2 N=72 Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
Melanoma
Primary: Disease Control Rate by Modified World Health Organization (mWHO) Tumor Assessment Criteria — 17.6; 4.8; 23.5; 9.5 Percentage of participants
Phase 2 N=70 Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
Solid Tumors · High Grade Gliomas · Lung Cancer
Primary: Test Image and Retest Image Reproducibility of Fluciclatide Injection ([18F]AH111585) Uptake by Solid Tumors Following Intravenous Administration of AH111585 (18F)…
Phase 2 N=961 Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma
Asthma · GERD
Primary: Mean Change in Morning Peak Expiratory Flow (mPEF (L/Minute)) From Baseline (Mean of the Last 7 Days in the run-in Period) to Treatment Period (Mean of All Available…
Phase 2 N=12 A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women
Phase 1 Pharmacodynamic Study
Primary: Pharmacodynamic Effect of Oral Calcitonin — 37.5; 100; 41.2; 44.4 percentage of time-matched placebo respo
Phase 2 N=45 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
Liver Cancer
Primary: Percentage of Participants With Objective Response (OR) — 9.1 percentage of participants
Phase 2 N=721 Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
Tetanus · Poliomyelitis · Hepatitis B
Primary: Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies. — 154; 165; 160; 197 Participants
Phase 2 N=18 A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response (pCR) — 22.22 percentage of participants
Phase 2 N=10 Glyburide Advantage in Malignant Edema and Stroke Pilot
Ischemic Stroke
Primary: Rate of Enrollment — 9.6 Months
Phase 2 N=23 Simvastatin Therapy in Smith-Lemli-Opitz Syndrome
Smith-Lemli-Opitz Syndrome
Primary: Serum Cholesterol to Total Sterol Ratio — 90.82; 93.99 percent total cholesterol — p=0.002
Phase 2 N=377 CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
Multiple Myeloma and Plasma Cell Neoplasm
Primary: The Number of Confirmed Hematologic Responses (Complete, Partial, or Very Good Partial Response) — 39; 11; 9; 10 participants
Phase 2 N=22 Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Breast Cancer · Breast Tumors · Neoplasms, Breast
Primary: Objective Response Rate (ORR) — 1 participants
Phase 2 N=75 Safety of Urate Elevation in Parkinson's Disease
Parkinson Disease
Primary: Tolerability — 96; 96; 100 percentage of participants